Brokerages Set Immix Biopharma, Inc. (NASDAQ:IMMX) Price Target at $20.67

Shares of Immix Biopharma, Inc. (NASDAQ:IMMX) have been assigned a consensus recommendation of “Moderate Buy” from the nine analysts that are currently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and seven have assigned a buy recommendation to the company. The average 1-year price objective among brokerages that have issued ratings on the stock in the last year is $20.6667.

IMMX has been the subject of a number of research analyst reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Immix Biopharma in a research report on Tuesday, April 21st. Citizens Jmp reissued a “market outperform” rating and set a $23.00 price target on shares of Immix Biopharma in a research report on Friday, March 27th. Bank of America began coverage on Immix Biopharma in a research note on Thursday, June 18th. They set a “buy” rating and a $27.00 price target on the stock. Mizuho lifted their price objective on Immix Biopharma from $14.00 to $15.00 and gave the company an “outperform” rating in a report on Monday, March 30th. Finally, Morgan Stanley started coverage on shares of Immix Biopharma in a research note on Wednesday, March 25th. They issued an “overweight” rating and a $20.00 price objective for the company.

Institutional Investors Weigh In On Immix Biopharma

Several hedge funds have recently modified their holdings of the business. Everhart Financial Group Inc. bought a new position in shares of Immix Biopharma during the second quarter valued at approximately $103,000. Bank of America Corp DE raised its stake in Immix Biopharma by 256,968.8% in the first quarter. Bank of America Corp DE now owns 41,131 shares of the company’s stock worth $375,000 after buying an additional 41,115 shares in the last quarter. Janus Henderson Group PLC lifted its holdings in Immix Biopharma by 22.5% during the first quarter. Janus Henderson Group PLC now owns 4,802,002 shares of the company’s stock worth $43,698,000 after buying an additional 880,434 shares during the period. The Manufacturers Life Insurance Company purchased a new stake in Immix Biopharma during the first quarter worth $264,000. Finally, Sei Investments Co. lifted its holdings in Immix Biopharma by 100.0% during the first quarter. Sei Investments Co. now owns 147,140 shares of the company’s stock worth $1,340,000 after buying an additional 73,570 shares during the period. Hedge funds and other institutional investors own 11.26% of the company’s stock.

Immix Biopharma Stock Performance

Immix Biopharma stock opened at $10.25 on Friday. The company has a 50 day moving average price of $9.49 and a 200-day moving average price of $8.41. Immix Biopharma has a fifty-two week low of $1.94 and a fifty-two week high of $12.14. The company has a market capitalization of $557.70 million, a PE ratio of -11.14 and a beta of 0.09.

Immix Biopharma (NASDAQ:IMMX) last announced its quarterly earnings results on Thursday, May 7th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.01. On average, analysts forecast that Immix Biopharma will post -0.69 earnings per share for the current year.

About Immix Biopharma

Immix Biopharma (NASDAQ:IMMX) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immuno-oncology therapies that target myeloid checkpoints. The company’s approach centers on harnessing the innate immune system to promote anti-tumor activity, complementing established T-cell checkpoint inhibitors. By modulating key myeloid pathways, Immix Biopharma aims to overcome resistance mechanisms in solid tumors and broaden the scope of effective cancer immunotherapy.

The company’s lead candidate, IMX-110, is a first-in-class combination therapy designed to activate macrophages and dendritic cells within the tumor microenvironment.